CME; insulin icodec, insulin, type 2 diabetes, T2D, ONWARDS

Overview
This educational program consists of 10 presentations on once-weekly basal insulin.
Use of daily basal insulins can be a burden and therefore result in decline or delay in initiation or discontinuation of insulin therapy in patients with type 2 diabetes. It would be beneficial to explore the development of more effective and simpler regimens that could support patients in extending their insulin therapy over a longer period of time.
Recently, trial data on once-weekly basal insulins have been published and one of the once-weekly formulations, insulin icodec, has been approved by the EMA and in other countries including Canada and Switzerland.
Join three experts in their discussions about the challenges related to use of once-daily basal insulins and how once-weekly basal insulins might be a helpful solution.
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Faculty:
Melanie Davies, MD
Leicester, United Kingdom
Professor Melanie Davies has acted as a consultant/advisor and speaker for Eli Lilly, Novo Nordisk and Sanofi, has attended advisory boards for Amgen, AstraZeneca, Biomea Fusion, Carmot/Roche, Sanofi, Zealand Pharma and Regeneron and as a speaker for AstraZeneca and Boehringer Ingelheim.
She has received grants from AstraZeneca, Boehringer Ingelheim and Novo Nordisk.

Chantal Mathieu, MD, PhD
Leuven, Belgium
Chantal Mathieu serves or has served on the advisory panel for Novo Nordisk, Sanofi, Eli Lilly and Company, Novartis, Dexcom, Boehringer Ingelheim, Bayer, Roche, Abbott, Medtronic, Insulet, Biomea Fusion, SAB Bio and Vertex. Financial compensation for these activities has been received by KU Leuven; KU Leuven has received research support for CM from Medtronic, Novo Nordisk and Sanofi; Chantal Mathieu serves or has served on the speakers bureau for Novo Nordisk, Sanofi, Eli Lilly and Company, Medtronic, Dexcom, Insulet, Abbott, Vertex and Boehringer Ingelheim. Financial compensation for these activities has been received by KU Leuven.
Chantal Mathieu is president of EASD. All external support of EASD is to be found on www.easd.org.
Athena Philis-Tsimikas, MD
La Jolla, CA, USA
Athena Philis-Tsimikas is an advisor and conduct research for Dexcom, Lilly, Novo, and AbbVie. All funds go to her employer with no transfer to Athena Philis-Tsimikas.

Reviewers/Content Planners/Authors:
- Tim Person has nothing to disclose.
- Anja Gerrits has no relevant relationships to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Discuss the role of insulin therapy in the management of diabetes, including its mechanisms of action, indications for use, and potential benefits in achieving glycemic control. 
- Summarize recent clinical trials investigating novel therapies for diabetes management, including their study designs, key findings, and implications for clinical practice. 
- Summarize the most recent clinical guidelines for the management of diabetes, highlighting key recommendations related to insulin therapy initiation, titration strategies, and monitoring.  
- Synthesize the latest evidence-based recommendations for insulin therapy from clinical guidelines and recent trials into a comprehensive, patient-centered approach to diabetes management to improve overall health outcomes for individuals with diabetes.
Target Audience
This activity has been designed to meet the educational needs of primary care physicians and endocrinologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with type 2diabetes.
Accreditation and Credit Designation Statements
This enduring activity is accredited by the European Board for Accreditation of Continuing Education for Health Professional (EBAC^®) for 64 minutes of effective education time.
EBAC^® holds an agreement on mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada, respectively.
Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals (EBAC^®) and the American Medical Association, physicians may convert EBAC^® External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC^®credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.
EBAC^® is a member of the International Academy for CPD Accreditation (IACPDA) and a partner member of the International Association of Medical Regulatory Authorities (IAMRA).
Provider(s)/Educational Partner(s)
Today’s healthcare environment is constantly evolving and advances of medical science occur at an accelerating pace. CME/CE plays an important role in the clinical environment and is an essential element of physician training, learning, and improvement, thereby importantly contributing to optimal patient care. Since 2000, MEDCON’s mission is to deliver high quality within the world of medical education by creating forums like PACE-CME, organizing live meetings, and providing online education. We aim to stimulate the review, exchange, and assimilation of key scientific findings to improve patients’ health, to raise awareness of new science underlying various disease states, and to accelerate the translation of this information into clinical practice.
Commercial Support
This activity is supported by an independent educational grant from Novo Nordisk A/S.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and PACE-CME This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of PACE-CME you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
System Requirements
- Supported Browsers (2 most recent versions):
- - Google Chrome for Windows, Mac OS, iOS, and Android
  - Apple Safari for Mac OS and iOS
  - Mozilla Firefox for Windows, Mac OS, iOS, and Android
  - Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 04/01/2025
Expiration Date: 04/01/2026